Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan(R), for the treatment of designated autoimmune diseases including multiple sclerosis.
Cyclophosphamide is the active drug used in Revimmune(TM) therapy, Accentia's proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2018
Arent there any generic versions of CTX on the market?
The original patent has long expired - will Accentia be able to get a new patent for a new indication (i.e. high dose CTX in MS)?
Is it generally possible to get new patents for an established Durg each and every time onecan prove efficacy for a new indication?
- Similar Topics
- Last post
- 0 Replies
- 1408 Views
Last post by ton
Fri Nov 09, 2018 11:14 am